MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • 2019 International Congress

    Osteopathic Manipulative Medicine to Improve Balance and Quality of Life in Parkinson Disease

    S. Yao, J. Docherty, J. Mancini, A. Leder, J. Difrancisco-Donoghue (Old Westbury, NY, USA)

    Objective: To examine the effects of Osteopathic Manipulative Medicine (OMM) using a pre-defined protocol for 6 weeks and compare that to a 6-week counseling protocol…
  • 2019 International Congress

    Advanced Stage of Parkinson’s Disease: From Identification to Characterization and Disease Burden Assessment Using a Nationwide Database

    Y. Barer, T. Gurevich, G. Chodick, N. Giladi, R. Gross, R. Cohen, L. Bergmann, Y. Jalundhwala, V. Shalev, A. Thaler (Tel Aviv-Yafo, Israel)

    Objective: To identify and describe PD patients who were prescribed intensified therapy and compare their burden of disease with mild-moderate PD patients. Background: Real-world data…
  • 2019 International Congress

    Clinical and DAT Imaging Characteristics of Participants with Scans without Evidence of Dopaminergic Deficit (SWEDDs): PPMI Cohort 2 year follow-up

    K. Marek, T. Simuni, A. Siderowf, D. Lafontant, C. Caspell-Garcia, C. Coffey, B. Mollenhauer, C. Tanner, K. Kieburtz, L. Chahine, J. Seibyl (New Haven, CT, USA)

    Objective: To examine the clinical and biological characteristics of participants with scans without evidence of dopaminergic deficit (SWEDD) during a two-year follow-up. Background: Study participants…
  • 2019 International Congress

    Translating Preclinical Data to a Human Equivalent Dose for AMT-130 AAV Gene Therapy for Early Manifest Huntington’s Disease

    M. Evers, M. de Haan, A. Valles-Sanchez, E. Sawyer, S. Gill, R. Roos, S. van Deventer, P. Konstantinova, J. Higgins (Amsterdam, Netherlands)

    Objective: To extrapolate the human equivalent dose (HED) for a Phase I/II clinical trial in adults to explore the safety, tolerability, and efficacy of striatally-administered…
  • 2019 International Congress

    MRI, Clinical, and Neuropathological Findings after Bilateral Intra-striatal Administration of rAAV5-miHTT in Non-human Primates

    J. Higgins, B. Blits, L. Spronck, A. Valles-Sanchez, M. Evers, S. van Deventer, P. Konstantinova, M. de Haan (Lexington, MA, USA)

    Objective: To assess the effects of intra-striatal administration of a huntingtin protein (HTT) lowering gene therapy in macaca fascicularis non-human primates (NHP). Background: The aggregation…
  • 2019 International Congress

    Magnetic Resonance Spectroscopy Evaluation of Neuronal Integrity and Astrocytosis in a Phase 2 Study of Laquinimod as a Treatment for Huntington Disease (LEGATO-HD)

    B. Leavitt, R. Reilmann, M. Gordon, K. Anderson, A. Feigin, S. Tabrizi, J. Stout, P. Piccini, B. Russell-Schulz, A. Mackay, B. Borowsky, G. Rynkowski, R. Volkinshtein, J. Savola, M. Hayden (Vancouver, BC, Canada)

    Objective: Evaluate the effect of laquinimod on putaminal and frontal white matter markers of neuronal integrity and astrocytosis using magnetic resonance spectroscopy (MRS) in patients…
  • 2018 International Congress

    SURE-PD3 Trial Participant Features prior to Randomization

    E. Macklin, A. Videnovic, C. Lungu, C. Kamp, C. Casaceli, D. Oakes, A. Ascherio, M. Schwarzschild; on behalf of the Parkinson Study Group SURE-PD3_Investigators (Boston, MA, USA)

    Objective: To describe the cohort screened and randomized into the Study of Urate Elevation in Parkinson’s Disease, phase 3 (SURE-PD3) trial (NCT02642393). Background: The SURE-PD3…
  • 2018 International Congress

    It takes two to tango but following may be more beneficial for rehabilitating people with mild-moderate Parkinson’s

    M. Hackney, A. Hart, C. Kim (Atlanta, GA, USA)

    Objective: This study determined the efficacy of internally guided (leading) versus externally guided (following) in adapted tango versus a contact-matched control group (wellness education) for…
  • 2018 International Congress

    Neurorestorative effects of glycine transporter 1-inhibitor and D-Serine in a mouse model of nigrostriatal dopaminergic degeneration

    V. Francardo, Y. Schmitz, D. Sulzer, M.A. Cenci (Lund, Sweden)

    Objective: We set out to evaluate potential neurorestorative effects of the GlyT1 inhibitor ACPPB vis-à-vis D-Serine in the intrastriatal 6-OHDA mouse model of Parkinson’s disease.…
  • 2018 International Congress

    Surface mechanised nano-formulation of naringenin as adenosine A2A receptor antagonist against in Neurological associated problem of Parkinson

    V. Kumar (Allahabad, India)

    Objective: In the current experimental study, we intended to develop Surface mechanized nano-formulation of naringenin (NG) as potent A(2A)AR antagonists against parkinson’s disease. Background: One…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley